Cellectar Biosciences, Inc.
CLRB Nasdaq
SEC CIK 1279704
Follow Cellectar Biosciences
Weekly email: filings, results
Net income
−$8M
−79.5% vs same quarter last year
EPS, diluted
−$0.46
+67.4% vs same quarter last year
Operating cash flow
−$9.4M
−120.2% vs same quarter last year
Operating income
−$8.1M
−67.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$21.8M |
| FY24 | −$44.6M |
| FY23 | −$38M |
| FY22 | −$31.8M |
| FY21 | −$24.1M |
| FY20 | −$15.1M |
| FY19 | −$14.1M |
| FY18 | −$13.2M |
| FY17 | −$13.6M |
| FY16 | −$6.2M |
| FY15 | −$5.5M |
| FY14 | −$8.1M |
| FY13 | −$10.8M |
| FY12 | −$8.8M |
| FY11 | −$7.4M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$23.1M |
| FY24 | −$47.7M |
| FY23 | −$33.2M |
| FY22 | −$25.4M |
| FY21 | −$22.7M |
| FY20 | −$14M |
| FY19 | −$11.7M |
| FY18 | −$11.8M |
| FY17 | −$11.4M |
| FY16 | −$8.4M |
| FY15 | −$8.3M |
| FY14 | −$8.9M |
| FY13 | −$9.3M |
| FY12 | −$6.7M |
| FY11 | −$6.1M |